AI Science Tracker
EN

Predicting Blood Concentration of Tacrolimus in Patients With Autoimmune Diseases Using Machine Learning Techniques Based on Real-World Evidence

University of Tsukuba; Tsukuba Medical Center Hospital · 24 Sep 2021 · medicine

Discovery

Predicting Blood Concentration of Tacrolimus in Patients With Autoimmune Diseases Using Machine Learning Techniques Based on Real-World Evidence

Source check: Source checked. Not independent scientific confirmation.

Finding: Among 193 tacrolimus therapeutic-drug-monitoring observations from 123 patients with autoimmune diseases, XGBoost was the best-performing one of 14 tested models for predicting blood concentration (R²=0.54). This retrospective cohort result does not establish improved dosing or clinical outcomes.

Technology: Supervised machine-learning models use patient and treatment variables to predict tacrolimus blood concentration.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Supervised machine-learning models use patient and treatment variables to predict tacrolimus blood concentration.
Test and result
Models were trained and assessed using observations from 123 patients; XGBoost reported R² 0.54.
Limitation / still unknown
Small retrospective dataset without external validation; dosing utility and patient outcomes were not tested.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/articles/PMC8497784

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary source full text, including Methods and Results; first result-bearing version checked against primary publication metadata..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.